- Intensifying market competition combined with weak consumer confidence! Automotive and luxury sectors become Europe's financial reporting season "drag factors"
- Analyst Says $10+ XRP Price Is No Longer A Wild Target, But…
- Wayfair 2Q Active Customers 21.7M >W
- Rockwell Automation 3Q EPS $3.65 >ROK
- Rockwell Automation 3Q Adj EPS $3.49 >ROK
- The Hartford To Acquire Equitable's Employee Benefits Business >HIG
- UL Solutions 2Q Net $246M >ULS
- Rockwell Automation 3Q Net $408M >ROK
- UL Solutions 2Q Rev $816M >ULS
- Viatris declares quarterly dividend of $0.12 a share
- UL Solutions Q2 FY26 net income more than doubled to $254 million; revenue rises 5.2% to $816 million
- VERTEX PHARMACEUTICALS INC <VRTX.O>: STIFEL RAISES TARGET PRICE TO $500 FROM $466
- V2X INC <VVX.N>: STIFEL RAISES TARGET PRICE TO $102 FROM $79
- ONSEMI <ON.O>: STIFEL CUTS TARGET PRICE TO $90 FROM $107
- Micron’s production capacity sold out through 2027, analysts say
- Merck 2Q FY26 net loss widens to $1.34 billion; sales rise 5% to $16.61 billion
- JAZZ PHARMACEUTICALS PLC <JAZZ.O>: STIFEL RAISES TARGET PRICE TO $275 FROM $230
- Entering the window to break the previous high for the third time, can Good Future (TAL.US) deliver a good stock price with good results?
- Spot gold has just broken through the $4060.00 per ounce mark, now quoted at $4060.03 per ounce, up 0.12% on the day; the main COMEX gold futures contract is now quoted at $4115.90 per ounce, up 0.62% on the day.
- US crude oil continuous contract plunged by $1.28 per barrel in the short term, hitting a low of $80.61 per barrel. Brent crude oil dropped $1.33 per barrel in the short term, hitting a low of $84.33 per barrel, as Qatar stated that a draft text has been prepared for a possible US-Iran agreement.
- Pfizer reports second quarter revenue of $15.03 billion, compared to an estimate of $14.41 billion. Adjusted earnings per share for the second quarter are $0.77. Pfizer expects full-year revenue between $60.5 billion and $62.5 billion, with the market estimate at $61.76 billion.
- The main contract of Nymex crude oil futures has just surpassed the $81.00 per barrel mark, with the latest quote at $80.99 per barrel, up 0.81% on the day.
- Brent crude oil futures have just surpassed the $85.00 per barrel mark, currently quoted at $84.98 per barrel, up 1.74% on the day.
- INSPIRE MEDICAL SYSTEMS INC <INSP.N>: STIFEL RAISES TARGET PRICE TO $75 FROM $65
- BRIEF-AMETEK Q2 EPS USD 1.77
- Ametek Q2 FY26 adjusted EPS rises 17% to $2.09; net sales increase 15% to $2.04 billion
- Wheels Up Q2 FY26 net loss widens 30% to $107.25 million; revenue drops 4% to $182 million
- Ryder CEO John Diez speaks at Deutsche Bank Chicago Industrials Summit webcast
- Surf Air Mobility posts updated investor presentation on IR website
- Ametek 2Q Net $406.9M >AME
- Ametek 2Q EPS $1.77 >AME
- Ametek 2Q Adj EPS $2.09 >AME
- Ametek 2Q Sales $2.04B >AME
- HEXCEL CORPORATION <HXL.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $100 FROM $94
- MOHAWK <MHK.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $121 FROM $109
- RBC BEARINGS <RBC.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $686 FROM $676
- BOWHEAD <BOW.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $34 FROM $31
- BOWHEAD <BOW.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $34 FROM $31
- RALPH LAUREN <RL.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $441 FROM $437
- ETHOS TECHNOLOGIES <LIFE.O>: DEUTSCHE BANK RAISES TARGET PRICE TO $40 FROM $30
- ECHOSTAR CORP. <ECHO.O>: DEUTSCHE BANK CUTS TARGET PRICE TO $118 FROM $137
- HILTON GRAND VACATIONS <HGV.N>: DEUTSCHE BANK CUTS TARGET PRICE TO $62 FROM $65
- CLOROX <CLX.N>: DEUTSCHE BANK RAISES TARGET PRICE TO $98 FROM $94
- MARRIOTT INTERNATIONAL INC. <MAR.O>: DEUTSCHE BANK CUTS TARGET PRICE TO $372 FROM $379
- Arbitrage Investment: David Bolat holds 23.17% voting rights via HBC Europa GmbH
- BACKBLAZE INC <BLZE.O>: NEEDHAM RAISES TARGET PRICE TO $23 FROM $14
- BRIEF-Timken Q2 Sales USD 1,260 Million Vs. IBES Estimate USD 1,233 Million
- Timken 2Q26 diluted EPS drops 63.4% to $0.41; net sales rise 7.5% to $1.26 billion vs FY25
- AAVE holds above $90 as protocol deposits rise, but retail demand weakens
- Blackstone Digital Infrastructure Trust Q2 FY26 net income rises to $7.1 million; GAAP EPS climbs to $0.14
- PDF SOLUTIONS INC : WELLS FARGO INITIATES COVERAGE WITH EQUAL WEIGHT RATING; TARGET PRICE $50
- Artemis Gold targets Q4 2026 commissioning for $120 million Blackwater Phase 1A expansion
- ONSEMI <ON.O>: NEEDHAM CUTS TARGET PRICE TO $116 FROM $130
- BRIEF-Energizer Holdings Q3 Adjusted EPS USD 0.75 Vs. IBES Estimate USD 0.83
- BRIEF-Kimco Realty Q2 Net Income USD 145.8 Million
- Energizer FY26 Q3 EPS drops 72.8% to $0.58; net sales rise 1.2% to $734.1 million
- OLIN CORP <OLN.N>: WELLS FARGO CUTS TO EQUAL WEIGHT FROM OVERWEIGHT
- Kimco Q2 FY26 net income per share slips 4.35% to $0.22; revenue from rental properties rises 4.89% to $546.42 million
- Scotts Miracle-Gro lifts FY2026 adjusted EPS forecast to $4.30-$4.45
- Sophia Genetics publishes investor presentation on AI platform for precision medicine
- MPLX Q2 FY26 net income rises 2.77% to $1.08 billion
- Caterpillar forecasts 2026 sales, revenue growth in mid-to-high teens
- Kimco Realty Sees FY EPS $1.00-EPS $1.03 >KIM
- Kimco Realty 2Q Net $153.3M >KIM
- Kimco Realty 2Q FFO 46c/Shr >KIM
- Versigent Q2 FY26 net income rises 10.3% to $118 million; net sales increase 10.8% to $2.44 billion
- Marathon Petroleum Q2 FY26 net income more than doubled to $5.1 billion
- Senmiao Technology hires government relations adviser to advance US AI data center rollout
- Pfizer says Q2 2026 results beat expectations on non-COVID brand growth and cost discipline
- Glaston to publish half-year financial report for January-June 2026
- BioNTech Q2 2026 net loss widens to €820.8 million; revenue drops 59.52% to €105.6 million vs Q2 2025
- Pfizer: Current 2026 Financial Guidance Doesn't Anticipate Any Stock Buybacks >PFE
- Pfizer Q2 FY26 swings to net loss of USD 248 million; revenue rises 3% to USD 15 billion
- API GROUP CORP : WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $53
- SOPHiA Genetics Q2 IFRS net loss flat at USD 22.4 million; revenue rises 27% to USD 23.3 million
- Pfizer Sets $2.5 Billion Additional Anticipated Productivity Enhancement Savings Associated With Ongoing Initiatives >PFE
- Pfizer 2Q Loss Reflects $4.3 Billion in Non-Cash Intangible Asset Impairments >PFE
- BRIEF-Haverty Furniture Q2 EPS USD 0.32
- BRIEF-Pfizer Q2 Adjusted EPS USD 0.77 Vs. IBES Estimate USD 0.68
- BRIEF-Marathon Petroleum Q2 EPS USD 17.73
- Pfizer 2Q Revenue Rose 5% Operationally Excluding Contributions From Comirnaty, Paxlovid >PFE
- SONIC AUTOMOTIVE INC <SAH.N>: JP MORGAN CUTS TARGET PRICE TO $72 FROM $76
- Havertys FY26 Q2 diluted EPS more than doubled to $0.32; sales increase 7.7% to $194.9 million
- HawkEye 360 schedules conference call on second-quarter results
- Haverty Furniture 2Q EPS 32c >HVT
- Haverty Furniture 2Q Net $5.31M >HVT
- Haverty Furniture 2Q Sales $194.9M >HVT
- Marathon Petroleum 2Q EPS $17.73 >MPC
- Marathon Petroleum 2Q Adj EPS $17.73 >MPC
- Pfizer Sees 2026 Rev $60.5B-$62.5B >PFE
- Kimberly-Clark: 2Q Sales Rose 0.6% as Favorable Currency Impacts of 1.1% Were Partially Offset by Exit of CO's Private Label Diaper Business in US >KMB
- Kimberly-Clark: 2026 Adj. EPS Attributable to Co Are Expected to See Low-Single-Digit Decline on Constant-Currency Basis >KMB
- Kimberly-Clark: 2026 Adj EPS From Cont Ops Expected to Grow High Single Digits on Constant-Currency Basis Including an About 30% Increase in Income From Equity Cos Vs Yr-Ago >KMB
- Kimberly-Clark: 2026 Adjusted Operating Profit Now Expected to Grow Mid-Single Digits on Constant-Currency Basis >KMB
- Kimberly-Clark Now Sees 2026 Organic Sales Growth to Be About 100 Basis Points Below Its Weighted Average Category Growth in Categories and Countries It Competes, Currently 2% on Trailing 12-Month Basis >KMB
- Kimberly-Clark: 2Q North America Net Sales Includes 0.5% Impact From Exit of CO's Private Label Diaper Business in US >KMB
- Kimberly-Clark: 2Q North America Net Sales $2.7B, Down 1.2% >KMB
- Kimberly-Clark: Situation Expected to Further Impact Sales and Profit in Near Term >KMB
- Kimberly-Clark: Independent Testing Conducted by Government-Certified Third Party Confirmed Quality and Safety of Co's Products, Refuting the False Allegations >KMB
- Kimberly-Clark 2Q Organic Sales Growth Broadly in Line With Prior Year >KMB
